Sugi Predict

Sugi Predict / Targets / TET1

TET1

Methylcytosine dioxygenase TET1 · Q8NFU7 · TET1 on Sugi Atlas →

9,276 patent compounds predicted against TET1, 6,648 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL167151 SCHEMBL167151 0.47 3/20
SCHEMBL703592 SCHEMBL703592 1.00 2/20
SCHEMBL301027 SCHEMBL301027 0.64 2/20
SCHEMBL679992 SCHEMBL679992 0.58 2/20
SCHEMBL1088793 SCHEMBL1088793 0.56 2/20
SCHEMBL1581964 SCHEMBL1581964 0.52 2/20
SCHEMBL69869 SCHEMBL69869 0.51 2/20
SCHEMBL111826 SCHEMBL111826 0.51 2/20
SCHEMBL1447090 SCHEMBL1447090 0.51 2/20
SCHEMBL1465494 SCHEMBL1465494 0.51 2/20
SCHEMBL644794 SCHEMBL644794 0.50 2/20
SCHEMBL999633 SCHEMBL999633 0.50 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL998382) 0.49 2/20
SCHEMBL396197 SCHEMBL396197 0.46 2/20
2-Picolinic Acid 2-Picolinic Acid (SCHEMBL906741) 0.45 2/20
SCHEMBL349007 SCHEMBL349007 0.44 2/20
SCHEMBL348394 SCHEMBL348394 0.43 2/20
SCHEMBL348779 SCHEMBL348779 0.43 2/20
SCHEMBL1094226 SCHEMBL1094226 0.42 2/20
SCHEMBL1002512 SCHEMBL1002512 0.36 2/20

Clinical trials — most relevant to TET1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) PHASE2COMPLETED
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome PHASE1/PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
FdCyd and THU for Advanced Solid Tumors PHASE1COMPLETED
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Hydroxymethylation, Incident Type 2 Diabetes and Incident Obesity nanUNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test nanUNKNOWN
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies nanUNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Genetic Aspects of Vaginal Aging nanCOMPLETED
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL nanRECRUITING
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer nanRECRUITING
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction nanNOT_YET_RECRUITING
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy nanCOMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TET1 binder may also engage these)

ProteinNameSimilarity
Q3URK3 — 1.000 Q3URK3 →
Q925H1 — 0.998 Q925H1 →
A6NCI8 — 0.998 A6NCI8 →
Q9Y2F5 — 0.995 Q9Y2F5 →
Q3V0A6 — 0.995 Q3V0A6 →
Q6P1W5 — 0.995 Q6P1W5 →
ASH1L Histone-lysine N-methyltransferase ASH1L 0.995 landscape →
Q8BG36 — 0.993 Q8BG36 →
Q28DZ0 — 0.993 Q28DZ0 →
Q80U44 — 0.993 Q80U44 →
Q5QGS0 — 0.993 Q5QGS0 →
Q5DTW7 — 0.993 Q5DTW7 →
Q6NS59 — 0.993 Q6NS59 →
E9Q286 — 0.993 E9Q286 →
Q90469 — 0.992 Q90469 →
O35923 — 0.992 O35923 →
Q9YGT5 — 0.992 Q9YGT5 →
Q99MY8 — 0.991 Q99MY8 →
Q5EXX3 — 0.991 Q5EXX3 →
Q9P2H0 — 0.991 Q9P2H0 →
Q86XD8 — 0.991 Q86XD8 →
Q6J6I9 — 0.991 Q6J6I9 →
MKI67 Proliferation marker protein Ki-67 0.991 landscape →
Q9D5K4 — 0.991 Q9D5K4 →
Q499R0 — 0.990 Q499R0 →
Q0GGX2 — 0.990 Q0GGX2 →
Q5VWN6 — 0.990 Q5VWN6 →
Q8N3X6 — 0.990 Q8N3X6 →
Q9Z2U4 — 0.990 Q9Z2U4 →
A4IGL8 — 0.990 A4IGL8 →